Skip to main content Accessibility help

Outcomes and Genetic Relatedness of Carbapenem-Resistant Enterobacteriaceae at Detroit Medical Center

  • Dror Marchaim (a1), Teena Chopra (a1), Federico Perez (a2) (a3), Kayoko Hayakawa (a1), Paul R. Lephart (a4), Suchitha Bheemreddy (a1), Christopher Blunden (a1), Andrea M. Hujer (a2), Susan Rudin (a2), Maryann Shango (a1), Michelle Campbell (a1), Jastin Varkey (a1), Jessica Slim (a1), Farah Ahmad (a1), Diixa Patel (a1), Ting-Yi Chen (a1), Jason M. Pogue (a5), Hossein Salimnia (a4), Sorabh Dhar (a1), Robert A. Bonomo (a2) (a3) (a6) and Keith S. Kaye (a1)...



Carbapenem-resistant Enterobacteriaceae (CRE) are rapidly emerging in hospitals in the United States and are posing a significant threat. To better understand the transmission dynamics and the acquisition of resistant strains, a thorough analysis of epidemiologic and molecular characteristics was performed.


CRE isolated at Detroit Medical Center were analyzed from September 2008 to September 2009. blaKPC genes were investigated by polymerase chain reaction (PCR), and repetitive extragenic palindromic PCR (rep-PCR) was used to determine genetic similarity among strains. Epidemiologic and outcomes analyses were performed.


Ninety-two unique patient CRE isolates were recovered. Sixty-eight strains (74%) were Klebsiella pneumoniae, 7 were Klebsiella oxytoca, 15 were Enterobacter species, and 2 were Escherichia coli. Fifteen isolates (16%) were resistant to Colistin, 14 (16%) were resistant to tigecycline, and 2 were resistant to all antimicrobials tested. The mean ± standard deviation age of patients was 63 ± 2 years. Sixty patients (68%) were admitted to the hospital from long-term care facilities. Only 70% of patients received effective antimicrobial therapy when infection was suspected, with a mean time to appropriate therapy of 120 ± 23 hours following sample culturing. The mean length of hospitalization after sample culturing was 18.6 ± 2.5 days. Of 57 inpatients, 18 (32%) died in the hospital. Independent predictors for mortality were intensive care unit stay (odds ratio [OR], 15.8; P = .003) and co-colonization with CRE and either Acinetobacter baumannii or Pseudomonas aeruginosa (OR, 17.2; P = .006). Among K. pneumoniae CRE, rep-PCR revealed 2 genetically related strains that comprised 70% and 20% of isolates, respectively.


In this large U.S. cohort of patients with CRE infection, which reflects the modern continuum of medical care, co-colonization with CRE and A. baumannii or P. aeruginosa was associated with increased mortality. Two predominant clones of K. pneumoniae accounted for the majority of cases of CRE infection.


Corresponding author

Division of Infectious Diseases, 5 Hudson, Harper University Hospital, 3990 John R. Street, Detroit, MI 48201 (


Hide All
1.Yigit, H, Queenan, AM, Anderson, GJ, et al.Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents chemother 2001;45(4):11511161.
2.Patel, G, Huprikar, S, Factor, SH, Jenkins, SG, Calfee, DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29(12):10991106.
3.Bradford, PA, Bratu, S, Urban, C, et al.Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis 2004;39(1):5560.
4.Endimiani, A, Depasquale, JM, Forero, S, et al.Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system. J Antimicrob Chemother 2009;64(5):11021110.
5.Gasink, LB, Edelstein, PH, Lautenbach, E, Synnestvedt, M, Fish-man, NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol 2009;30(12):11801185.
6.Munoz-Price, LS, Hayden, MK, Lolans, K, et al.Successful control of an outbreak of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae at a long-term acute care hospital. Infect Control Hosp Epidemiol 2010;31(4):341347.
7.Hirsch, EB, Tam, VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010;65(6):11191125.
8.Leavitt, A, Navon-Venezia, S, Chmelnitsky, I, Schwaber, MJ, Carmeli, Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother 2007;51(8):30263029.
9.Samra, Z, Ofir, O, Lishtzinsky, Y, Madar-Shapiro, L, Bishara, J. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel. IntJ Antimicrob Agents 2007;30(6):525529.
10.Schwaber, MJ, Carmeli, Y. Carbapenem-resistant Enterobacteriaceae. a potential threat. JAMA 2008;300(24):29112913.
11.Souli, M, Galani, I, Antoniadou, A, et al.An outbreak of infection due to beta-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek university hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis 2010;50(3):364373.
12.Centers for Disease Control and Prevention. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 2009;58(10):256260.
13.Marchaim, D, Chopra, T, Pogue, JM, et al.Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother 2011;55(2):593599.
14.Paul, M, Shani, V, Muchtar, E, Kariv, G, Robenshtok, E, Leibovici, L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010;54(11):48514863.
15.Maltezou, HC, Giakkoupi, P, Maragos, A, et al.Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece). J Infect 2009;58(3):213219.
16.Zarkotou, O, Pournaras, S, Voulgari, E, et al.Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae, a matched case-control study. J Clin Microbiol 2010;48(6):22712274.
17.Dellinger, RP, Levy, MM, Carlet, JM, et al.Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36(1):296327.
18.Bion, JF, Edlin, SA, Ramsay, G, McCabe, S, Ledingham, IM. Validation of a prognostic score in critically ill patients undergoing transport. Br Med J (Clin Res Ed) 1985;291(6493):432434.
19.Charlson, ME, Pompei, P, Ales, KL, MacKenzie, CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40(5):373383.
20.Katz, S, Ford, AB, Moskowitz, RW, Jackson, BA, Jaffe, MW. Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963;185:914919.
21.Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: 19th Informational Supplement. CLSI approved standard M100-S19. Wayne, PA: CLSI, 2009.
22.Kitchel, B, Rasheed, JK, Endimiani, A, et al.Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2010;54(10)42014207.
23.Endimiani, A, Hujer, AM, Perez, F, et al.Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the eastern USA. J Antimicrob Chemother 2009;63(3):427437.
24.Yu, VL, Hansen, DS, Ko, WC, et al.Virulence characteristics of Klebsiella and clinical manifestations of K. pneumoniae bloodstream infections. Emerg Infect Dis 2007;13(7):986993.
25.Lat, A, Clock, SA, Wu, F, et al.Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs against KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest. J Clin Microbiol. 2011;49(5):17951798.
26.Munoz-Price, LS. Long-term acute care hospitals. Clin Infect Dis 2009;49(3):438443.
27.Schwaber, MJ, Klarfeld-Lidji, S, Navon-Venezia, S, Schwartz, D, Leavitt, A, Carmeli, Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008;52(3):10281033.
28.Perez, F, Endimiani, A, Ray, AJ, et al.Carbapenem-resistant Aci-netobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J Antimicrob Chemother 2010;65(8):18071818.
29.Sidjabat, HE, Silveira, FP, Potoski, BA, et al.Interspecies spread of Klebsiella pneumoniae carbapenemase gene in a single patient. Clin Infect Dis 2009;49(11):17361738.

Related content

Powered by UNSILO

Outcomes and Genetic Relatedness of Carbapenem-Resistant Enterobacteriaceae at Detroit Medical Center

  • Dror Marchaim (a1), Teena Chopra (a1), Federico Perez (a2) (a3), Kayoko Hayakawa (a1), Paul R. Lephart (a4), Suchitha Bheemreddy (a1), Christopher Blunden (a1), Andrea M. Hujer (a2), Susan Rudin (a2), Maryann Shango (a1), Michelle Campbell (a1), Jastin Varkey (a1), Jessica Slim (a1), Farah Ahmad (a1), Diixa Patel (a1), Ting-Yi Chen (a1), Jason M. Pogue (a5), Hossein Salimnia (a4), Sorabh Dhar (a1), Robert A. Bonomo (a2) (a3) (a6) and Keith S. Kaye (a1)...


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.